Clinical characteristics and survival outcomes of rectal cancer patients across different mrT3 substages determined by rectal MRI
International Journal of Colorectal Disease · 2025
DOI: 10.1007/s00384-025-04935-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Colorectal Disease, 2025. Verfasst von Ganbin Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuai …. Hauptthemen laut MEDLINE: Rectal Neoplasms, Magnetic Resonance Imaging, Rectum. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National High Level Hospital Clinical Research Funding.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: Locally advanced rectal cancer (LARC) staged as mrT3 could be further subdivided into mrT3a to T3d based on depth of tumor invasion through the muscularis propria. Limited evidence exists to compare the differences across subgroups. METHODS: Clinical data from patients between January 2018 and 2022 were collected. The study included patients with mrT3 LARC who received neoadjuvant chemoradiotherapy (NCRT). Based on depth of invasion through muscularis propria, patients were categorized into three groups: mrT3a ( 10 mm). The outcomes were disease-free survival (DFS), pathological complete response (pCR), tumor recurrence and metastasis. RESULTS: A total of 295 patients were identified, including 65 (22.0%) in mrT3a, 155 (52.5%) in mrT3b, and 75 (25.5%) in mrT3c~d group. The tumor vertical diameter was larger in mrT3c/d group (46.3 ± 13.7 mm), compared to mrT3a (39.4 ± 14.3 mm) and mrT3b (39.8 ± 12.1 mm) groups (P < 0.001). The positive rates of mesorectal fascia (61.3% vs. 30.3% vs. 7.7%, P < 0.001) and extramural vascular invasion (62.7% vs. 40.0% vs. 27.7%, P < 0.001) were significantly higher in mrT3c/d group compared to mrT3a and mrT3b groups. The estimated pCR rates were 33.9% for mrT3a, 32.3% for mrT3b, and 21.3% for mrT3c/d group (P = 0.172). The median follow-up time was 43 (29-58) months. The metastasis and local recurrence rates were 8.8% and 2.4%. The 3y-DFS rates were 92.2% for mrT3a, 87.7% for mrT3b, and 86.2% for mrT3c/d (P = 0.549). CONCLUSION: Despite mrT3c/d patients presenting with more aggressive baseline features, standardized NCRT followed by radical surgery effectively mitigated survival disparities across mrT3 substages. These findings suggest that mrT3 subclassification may not independently predict long-term survival outcomes when patients receive optimal multimodal therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuai Fu Yuan, Dong Cheng District, Beijing, 100730, China.
- Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuai Fu Yuan, Dong Cheng District, Beijing, 100730, China. linguole@126.com.
Förderung
- National High Level Hospital Clinical Research Funding
Zitieren
APA
Li, G., Zhang, X., Qiu, X., Xu, L., Lu, J., Wu, B., Xiao, Y., & Lin, G. (2025). Clinical characteristics and survival outcomes of rectal cancer patients across different mrT3 substages determined by rectal MRI. International Journal of Colorectal Disease. https://doi.org/10.1007/s00384-025-04935-5
Vancouver
Li G, Zhang X, Qiu X, Xu L, Lu J, Wu B, et al. Clinical characteristics and survival outcomes of rectal cancer patients across different mrT3 substages determined by rectal MRI. International Journal of Colorectal Disease. 2025. doi:10.1007/s00384-025-04935-5
BibTeX
@article{Li2025,
author = {Li, Ganbin and Zhang, Xiao and Qiu, Xiaoyuan and Xu, Lai and Lu, Junyang and Wu, Bin and Xiao, Yi and Lin, Guole},
title = {Clinical characteristics and survival outcomes of rectal cancer patients across different mrT3 substages determined by rectal MRI},
journal = {International Journal of Colorectal Disease},
year = {2025},
doi = {10.1007/s00384-025-04935-5}
}
EUVIMED